Rapid Information on OLM No.171 130114.docVIP

Rapid Information on Olmesartan and other ARBs No.171 2013/01/14　　 　　　　　　　　　　　　　　　　　 　　　　　　　　Be the first to know! 　　　 　　 (Toru Komai, Ph.D.) 171-1：Switching from failed monotherapy to a treatment regimen based on AML/OLM±HCTZ was well improved the achievement of BP goals in patients with hypertension, irrespective of diabetic status or presence of metabolic syndrome. Title：Efficacy of an amlodipine/olmesartan treatment algorithm in patients with or without type 2 diabetes and hypertension (a secondary analysis of the BP-CRUSH study). 　　　　　 2-3 171-2：Adding HCTZ to a range of OLM/AML dose combinations improved BP control by significantly lowering DBP and SBP and significantly increasing BP threshold achievement in patients with moderate-to-severe hypertension. Title：Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination. 3 171-3：In Japanese elderly high-risk hypertensive patients, olmesartan plus CCB combination therapy was more effective in prevention of cardiovascular events in patients with CKD compared with high-dose olmesartan therapy. (A subgroup analysis of the OSCAR study) Title：An angiotensin II receptor blocker-calcium channel blocker combination prevents cardiovascular events in elderly high-risk hypertensive patients with chronic kidney disease better than high-dose angiotensin II receptor blockade alone. 4-5 Abbreviations: BP: blood pressure, SBP: systolic BP, DBP: diastolic BP CVD: cardiovascular disease, CHF: chronic heart failure, CKD: chronic kidney disease, T2DM: type 2 diabetes mellitus, BNP: brain natriuretic peptide, OLM: olmesartan, AML: amlodipine, HCTZ: hydrochlorothiazide, CCB: calcium channel blocker, HR: hazard ratio, OR: odds ratio, 171-1：Switching from failed monotherapy to a treatment regimen based on AML/OLM±HCTZ was well impro